Lobe Sciences (XCNQ:LOBE) Cash-to-Debt : 0.01 (As of Feb. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Lobe Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Lobe Sciences's cash to debt ratio for the quarter that ended in Feb. 2024 was 0.01.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Lobe Sciences couldn't pay off its debt using the cash in hand for the quarter that ended in Feb. 2024.

The historical rank and industry rank for Lobe Sciences's Cash-to-Debt or its related term are showing as below:

XCNQ:LOBE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: No Debt Max: No Debt
Current: 0.01

During the past 13 years, Lobe Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was No Debt.

XCNQ:LOBE's Cash-to-Debt is ranked worse than
98.93% of 1492 companies
in the Biotechnology industry
Industry Median: 6.85 vs XCNQ:LOBE: 0.01

Lobe Sciences Cash-to-Debt Historical Data

The historical data trend for Lobe Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Lobe Sciences Cash-to-Debt Chart

Lobe Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Aug19

Aug20

Aug21

Aug22

Aug23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

0.57

No Debt

0.42

Lobe Sciences Quarterly Data
	Dec18	Mar19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	Aug23	Nov23	Feb24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	0.82	0.42	0.13	0.01

Competitive Comparison of Lobe Sciences's Cash-to-Debt

For the Biotechnology subindustry, Lobe Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lobe Sciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lobe Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Lobe Sciences's Cash-to-Debt falls into.

Lobe Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Lobe Sciences's Cash to Debt Ratio for the fiscal year that ended in Aug. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.14	/	(0.333	+	0)
	=	0.42

Lobe Sciences's Cash to Debt Ratio for the quarter that ended in Feb. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.005	/	(0.368	+	0)
	=	0.01

Lobe Sciences (XCNQ:LOBE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Lobe Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Lobe Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Lobe Sciences (XCNQ:LOBE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lobe Sciences Ltd (XCNQ:LOBE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

LOBEF:USA 6YX0:Germany

Address

1199 West Hastings Street, Suite 1400, Vancouver, BC, CAN, V6E 3T5

Website

https://www.lobesciences.com

Lobe Sciences Ltd is a technology and services company that provides real estate, financial, management, IP, and branding support for the development of transformational medicine. It is working to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications.

Lobe Sciences (XCNQ:LOBE) Headlines

No Headlines